PTK2 and neoplasm: They concluded CB1 receptor agonists by modulating FAK phosphorylation inhibited tumour cell invasion and metastasis and therefore CB1 receptor activation may represent a novel therapeutic target for the treatment of breast carcinoma and metastasis (Grimaldi et al. 2006).